Get caught up with the latest study information, feedback from people in the field, and news on the latest investigational therapies.
Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.
Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.
he latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.
C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.
By analyzing 38 strains from patients, researchers identified clusters linked to frequent room changes, highlighting the need for improved infection control measures.
